Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.30B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 3.38M
Average 2.73M
TSHA Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Taysha Gene Therapies, Inc.NASDAQ: TSHA
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables outflow grows to $0
Q2 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.
Context
- Accounts receivables amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How TSHA compares with its peers on the latest reported figures
- TSHA's LTM Jun 2026 accounts receivables of $0 is the 6th largest of the 9 companies compared; the peer median is $4.04K.
- Accounts receivables amounts to 0.0% of revenue for TSHA, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $264.55M | +194.3% | — | 12.1% | |
| LTM Mar 2026 | $9.02M | +328.9% | — | 10.3% | |
| LTM Mar 2026 | $5.09M | -985.6% | — | 35.0% | |
| LTM Mar 2026 | $465K | -65.5% | -17.4% | 1.3% | |
| LTM Mar 2026 | $8.07K | -96.4% | +481.9% | — | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding TSHA) | $4.04K | -65.5% | +232.2% | 10.3% | |
Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Depreciation & Amortization | 492K | 1.17M | 1.37M | 1.25M | 1.15M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 18.18M | 18.04M | 7.91M | 13.1M | 13.3M |
| Change in Working Capital | 28.67M | 18.52M | (18.01M) | (12.47M) | (5.37M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 14.49M | (7.8M) | (2.3M) | (2.92M) | (153K) |
| Other Working Capital | 14.17M | 26.32M | (15.72M) | (9.55M) | (5.22M) |
| Other Non-Cash Items | 10.14M | 39.89M | 47.28M | 6.19M | 6.83M |
| Operating Cash Flow | (117.04M) | (88.39M) | (73.02M) | (81.23M) | (93.09M) |
| Capital Expenditures | (21.55M) | (24.87M) | (7.37M) | (374K) | (738K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (6.25M) | (61K) | (3.48M) | 11K | 134K |
| Investing Cash Flow | (21.55M) | (24.93M) | (7.35M) | (363K) | (604K) |
| Debt Repayment | 39.96M | 0 | (3.45M) | 0 | 9.24M |
| Common Stock Issued | (360K) | 53.24M | 140.79M | 76.78M | 265.69M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (514K) | (1.15M) | (947K) | (96K) | (337K) |
| Financing Cash Flow | 39.08M | 52.1M | 136.39M | 76.68M | 274.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (99.51M) | (61.22M) | 56.02M | (4.9M) | 180.9M |
| Free Cash Flow | (138.6M) | (113.26M) | (80.39M) | (81.6M) | (93.83M) |
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.